Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMUS 001: FOLFOX-A vs AG in Metastatic Pancreatic Cancer
NCT04151277Phase 2Recruiting
- Start
- Nov 2017
- Primary completion
- Dec 2025
- Modality
- Polymer-based Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nab-paclitaxel and oxaliplatin in pancreatic adenocarcinoma (PDAC) (2 arms). Primary endpoint: Progression Free Survival. Started Nov 2017; status: recruiting.
02
Drugs
nab-paclitaxeloxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04151277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04151277.